Gilead Sciences

Gilead reports final outcomes from trial of bulevirtide for chronic HDV
Clinical Trials Arena
Thu, 05/8/25 - 11:06 am
Gilead Sciences
clinical trials
hepatitis D
buleviritide
Gilead boosts planned US investments by $11 billion amid tariff threat
Yahoo/Reuters
Wed, 05/7/25 - 11:01 pm
Gilead Sciences
tariffs
drug manufacturing
Gilead enters $202M settlement to resolve US government's long-running HIV kickbacks probe
Fierce Pharma
Wed, 04/30/25 - 11:02 am
Gilead Sciences
HIV
legal
DOJ
kickbacks
Gilead Dives After Its Bread-And-Butter Drug Misses Sales Forecasts
Investors Business Daily
Thu, 04/24/25 - 09:18 pm
Gilead Sciences
earnings
Biktarvy
Trodelvy
Trodelvy-Keytruda combo improves cancer trial outcomes
Investing.com
Mon, 04/21/25 - 11:11 am
Gilead Sciences
Trodelvy
Keytruda
Merck
metastatic triple-negative breast cancer
The 5 largest biopharma layoffs of Q1 2025
BioSpace
Fri, 04/11/25 - 11:47 am
layoffs
Novartis
Galapagos
Bristol Myers Squibb
Merck
Gilead Sciences
In Bay Area, Gilead cuts 149 positions and Roche's diagnostics division lays off 108
Fierce Pharma
Mon, 04/7/25 - 11:22 pm
Gilead Sciences
Roche
layoffs
California
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
Fierce Pharma
Tue, 03/11/25 - 07:10 pm
Gilead Sciences
lenacapavir
HUV
PrEP
FDA sets June date for Gilead's twice-yearly HIV PrEP
Pharmaphorum
Wed, 02/19/25 - 09:42 am
Gilead Sciences
FDA
PrEP
HIV
lenacapavir
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Fierce Biotech
Tue, 02/18/25 - 11:02 pm
Arcus Biosciences
Merck
Gilead Sciences
Welireg
kidney cancer
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
Fierce Pharma
Wed, 02/12/25 - 11:16 am
Gilead Sciences
HIV
PrEP
lenacapavir
Gilead Sciences Beats Q4 EPS Forecast
Motley Fool
Tue, 02/11/25 - 09:51 pm
Gilead Sciences
earnings
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
Fierce Pharma
Mon, 02/10/25 - 10:14 am
Bristol Myers Squibb
Breyanzi
CAR-T
marginal zone lymphoma
Gilead Sciences
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy
Fierce Pharma
Thu, 01/16/25 - 11:08 am
Gilead Sciences
DOJ
HHS
patents
Truvada
Descovy
legal
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Fierce Biotech
Mon, 01/13/25 - 11:03 am
Gilead Sciences
JPMHC 2025
LEO Pharma
inflammation
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
BioSpace
Thu, 12/19/24 - 11:27 am
Gilead Sciences
Assembly Bio
funding
hepatitis D
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
Fierce Pharma
Thu, 12/12/24 - 11:44 pm
ICER
drug pricing
Gilead Sciences
JNJ
Novartis
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
Wed, 12/11/24 - 11:40 am
Gilead Sciences
Biktarvy
patent cliffs
HIV
Can CAR-T first movers keep pace in a rapidly evolving market?
Pharmaphorum
Wed, 12/11/24 - 10:59 am
CAR-T
Gilead Sciences
Novartis
Gilead/Arcellx’s anito-cel’s differentiated safety profile challenges J&J/Legend’s Carvykti
BioSpace
Tue, 12/10/24 - 11:41 am
Gilead Sciences
Arcellx
anito-cel
JNJ
Carvykti
Multiple Myeloma

Pages